Navigation Links
ThromboGenics Announces Half Year Results 2008
Date:8/28/2008

LEUVEN, Belgium, August 28 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update and its financial results for the six month period ending June 30, 2008.

During the first half of 2008, ThromboGenics has achieved a number of key milestones which have positioned the Company to successfully pursue the next stage of its corporate strategy. In this period, ThromboGenics signed a high value strategic alliance with Roche for its novel anti-cancer product TB-403 and has seen important new clinical data for its lead product, microplasmin, in patients with back of the eye disease. Given this progress, ThromboGenics is confident that the next twelve months will see further significant shareholder value being generated as it continues to maximise value from its product pipeline.
2008 highlights

Partnership

- Major partnering deal: In June, ThromboGenics and its co-development

partner BioInvent signed a strategic alliance deal with Roche for its

novel anti-cancer agent, TB-403 (anti-PIGF). Under the terms of the

agreement ThromboGenics and BioInvent received an upfront payment of

EUR50 million and could potentially share up to EUR450 million in

milestone payments as well as double digit royalties. TB-403 is a novel

monoclonal antibody which blocks Placental Growth Factor (PIGF), one of

the growth factors responsible for the development of new blood

vessels. TB-403 is being developed as an anti-cancer agent, and is

currently in Phase I of clinical development. It acts by selectively

inhibiting tumor growth by blocking its blood supply without affecting

normal tissues.

Clinical Highlights

- TB-403 : Positive results announced in first Phase Ia study

with TB-403 and start of Phase Ib study in late stage cance
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
2. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
3. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
4. ThromboGenics N.V. - Business Update
5. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
6. ThromboGenics Announces 2007 Full Year Results
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
9. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
10. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
11. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Product and process impurities in biopharmaceuticals ... are often “lost in the noise,” making their ... Dr. Rowel Tobias, Senior Scientist, Protein Chemistry at ... Quality at Nanotherapeutics, Inc., to lear about a ... and quantitation while achieving the required specificity and ...
(Date:7/10/2014)... July 10, 2014 Unraveling life’s mysteries ... The Archer Family purchased a DNA test ... but ended up with a lifetime of memories, sharing, ... the family members’ DNA genuinely brought the family closer ... search deeper into genetic history and prior to taking ...
(Date:7/10/2014)... 2014 Senior supply chain management executives ... addressed the challenges of “Reducing Cost, Lead Time, & ... strategic sourcing. Describing the partnership of the Bio Supply ... Management Institute ( SCMI) of the University of ... at the Kroc Institute of Peace and Justice in ...
(Date:7/10/2014)... , July 10, 2014 /PRNewswire-iReach/ -- Tute ... interpretation, today announced an agreement with Lineagen, ... for Lineagen,s NextStep Dx PLUS.  Lineagen, ... and neurological disorders, currently offers FirstStep Dx ... testing service used by healthcare providers as ...
Breaking Biology Technology:Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4
... Jan. 5 Pharmatech, Inc. announces the launch of ... in oncology,along with other key company developments that will ... Pharmatech will feature a name change,from Pharmatech, Inc. to ... site,and emerging roles and responsibilities of the executive leadership ...
... Mach One Corporation,(Pink Sheets: MNCN), a biological solutions ... benefit to the agricultural and consumer,market, announced today that ... December 30, 2008 related to a proposed transaction with ... "BioPharm") to,acquire all of the outstanding member interests of ...
... Penn Allegheny,Health System and The Western Pennsylvania Hospital announced ... Jones, MD, FACS,and Roger R. Barrette, MD, formerly of ... Drs. Jones and Barrette will direct the ... for the treatment of burn injuries. West Penn,is ...
Cached Biology Technology:Pharmatech 2.0: Introducing Pharmatech Oncology 2Mach One Corporation Enters Letter of Intent 2West Penn Allegheny Health System Announces Recruitment of Leading Burn Specialists 2West Penn Allegheny Health System Announces Recruitment of Leading Burn Specialists 3
(Date:7/10/2014)... cities in New Mexico, nearly every public golf course ... precious potable water supplies. Across the U.S. Southwest as ... receive treated effluent. Reusing the effluent increases the sustainability ... homeowners alike fertilize their lawns during the growing season. ... Mexico State University turfgrass expert has a new vision ...
(Date:7/10/2014)... 2014 Smart technology emphasis grows in ... improved security: NXT-ID, Inc. (OTCBB: NXTD), eBay Inc. (NASDAQ: ... Apple Inc. (NASDAQ: AAPL ), Visa Inc. (NYSE: ... NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused on ... second series of 30 second spots on CNBC for its ...
(Date:7/10/2014)... -- According to the new market research ... Material (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), Application (Mobile ... Finance), and Geography - Global Trends & Forecasts to ... Sensors Market is projected to cross $14.35 Billion by ... 2014 to 2020. Browse more than 78 ...
Breaking Biology News(10 mins):'Tailored' water -- the latest in lawn care 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3
... The Patagonian Hippidion horse genus and North American stilt-legged ... tree, according to a new article in the open ... Alan Cooper, and colleagues use ancient DNA to argue ... and that American stilt-legged horses were American endemics, not ...
... of Toronto have mapped the molecular details that show ... immortalizes cells and causes them to continuously grow, thereby ... virus (EBV) is one of the most common human ... certain b-cell cancers like Burkitt's lymphoma as well as ...
... there's a recent wiki article with more details . New ... rat? A Guinea pig? Try none of the above. , A ... rodent with stubby legs and a tail covered in dense hair. ... actually more like a guinea pig or chinchilla. But not quite. ...
Cached Biology News:Ancient DNA helps clarify the origins of two extinct New World horse species 2U of T researchers map role of Epstein-Barr virus in cancer 2Scientists discover odd-ball rodent 2
... designed to rapidly and reliably amplify unknown ... Technology. APAgene provides hassle-free, ready-to use components, ... ingredients are provided in each kit. The ... gap filling, localized cloning of genomic DNA, ...
Rabbit polyclonal to Quinaldic Acid ( Abpromise for all tested applications). Antigen: Synthetic peptide Quinaldic Acid conjugated to a protein carrier....
Mol wt: average mol wt16,951.27 Da by calculation...
A set of five peptides which can be used to calibrate a Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) or Electrospray Ionization (ESI) mass spectrometer....
Biology Products: